Diverse Biotech Medical Team

Our Inventors

Pioneering Science | A Proven Track Record of Success

Paul Hershberger, PhD

Chief Chemist

Philip Arlen, PhD

Chief Scientific Officer

Our Medical Team

World-Class Expertise | A Renowned Scientific Advisory Board

Armand B. Cognetta Jr, MD

Florida State University
Dr. Cognetta is one of the nation’s leading dermatologists. Dr. Cognetta is founder and president of Dermatology Associates of Tallahassee. He started practicing under the Dermatology Associates namesake in June 1985. He received his medical degree from the University of Connecticut Medical School in 1979, served his residency at Tallahassee Memorial Hospital, and served his dermatology residency at the University of Alabama in Birmingham. Dr. Cognetta also served his MOHs Fellowship at the University of Alabama in Birmingham. Dr. Cognetta is an associate professor of dermatology at the Florida State University School of Medicine. Dr. Cognetta is also a Clinical professor and Chief of the Division of Dermatology for the FSU College of Medicine. He is also a fellowship director at the American College of MOHs Micrographic Surgery and Cutaneous Oncology. Dr. Cognetta is widely published and lectures on early detection of melanoma and skin cancer management. He also currently trains one Fellow a year for the American College of MOHs Micrographic Surgery and Cutaneous Oncology. Dr. Cognetta and his staff currently specialize in the early detection and treatment of skin cancer.

Neal D. Shore, MD, FACS

Director, CPI, Carolina Urologic Research Center
Neal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr. Shore has conducted more than 350 clinical trials, focusing mainly on GU Oncology, and serves on the Executive Boards of: Society of Urologic Oncology Board and the Bladder Cancer Advocacy Network. He serves as the National Urology Research Director for 21st Century Oncology. He has served on the AUA Male Health Committee and the AUA Data Committee, the SITC Task Force for Prostate Cancer, the Bladder Cancer Advocacy Think Tank and the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE(Academic Editor), World Journal of Urology, and serves as Editor, Everyday Urology-Oncology. He has more than 200 peer reviewed publications and numerous book chapters; he performs peer review for Lancet Oncology, New England Journal of Medicine, European Urology, Journal Urology, Urology, BJUI, PCPD, and numerous other high impact scientific journals. A graduate of Duke University and Duke University Medical School, Dr. Shore completed a 6- month clinical research fellowship in Pretoria, South Africa, and then completed his General Surgery/Urology training at New York Hospital Cornell Medical Center and at Memorial Sloan- Kettering Cancer Center in New York City. He is a Fellow of the American College of Surgeons.

Douglas Heldreth, MD

Florida Cancer Specialists
Dr. Douglas Heldreth is a board-certified oncologist for Florida Cancer Specialists & Research Institute. Dr. Heldreth received his medical degree from West Virginia University School of Medicine in Morgantown, WV. He completed an internship in Internal Medicine at Charleston Area Medical Center in Charlestown, WV and a residency in Internal Medicine at Orlando Regional Medical Center/University of Florida. Dr. Heldreth gained additional training through a fellowship in Medical Oncology at the University of South Florida College of Medicine in Tampa and frequently serves as a sub-investigator for Phase 1, 2 and 3 clinical trial research studies.

Joyce Ann O’Shaughnessy, MD

Texas Oncology & US Oncology Research
Dr. O’Shaughnessy is considered to be one of the top three experts in breast cancer in the United States. Dr. O’Shaughnessy focuses on breast cancer prevention and treatment. She is Co-Chair of Breast Cancer Research and Chair of Breast Cancer Prevention Research at Baylor-Sammons Cancer Center and for The US Oncology Network and is a member of the Scientific Advisory Board for US Oncology Research Network.

Dr. John Patrick, MD

Virginia Commonwealth University
Dr. John Patrick is our Executive Vice President and Chief Medical Officer. He earned his MD from the Medical College of Virginia, now Virginia Commonwealth University. He is a board certified and practicing anesthesiologist who is also an active high-level entrepreneur. Dr. John is our Chairman of the Medical Committee, directing and consulting with national experts for our upcoming clinical trials. He is also an active member of the Board of Directors of Diverse Biotech, assisting in expanding the Company's intellectual property and has been instrumental in driving the Company's capital raises.

Michael Vaughn, MD, PhD.

Medical College of Virginia/ VCU
Michael P. Vaughn, MD, PhD is our Director of Clinical Development. Dr. Vaughn earned his PhD training at the Department of Microbiology and Immunology at the Medical College of Virginia/ VCU and was sponsored by an NIH training grant. His laboratory experience in Transplant and Cancer Immunology began even prior to his Medical training. Dr. Vaughn is Board Certified in Internal Medicine, Emergency Medicine, and Allergy, & Immunology (A&I). He currently practices part-time in A&I and in 2023 was selected by his peers as one of San Antonio’s “Best Doctors” in his field of practice.

William Fisher, MBA

Wharton Business School
William Fisher, founder of Diverse Biotech, is revolutionizing cancer treatment through groundbreaking drug discovery. Building upon a scientific background he has gained and developed through extensive business operations, he assembled a world-class team of respected doctors and scientists, leading the charge in inventing a novel class of drugs that has shown promising results in preclinical trials. A risk-taker and thrill-seeker, William's pursuits extend beyond the boardroom to motorcycle racing, offshore fishing, and piloting aircraft. His visionary leadership has propelled Diverse Biotech to the forefront of transformative cancer therapies.

Ron Menezes

Brigham Young University
Ron is a member of the Board of Directors with 20+ years of experience across publicly-traded healthcare, life sciences, pharmaceutical, aesthetics and medical device companies, such as AltrixBio, Vera Biotechnologies Inc., Sientra Inc., Almirall U.S., Allergan, Abbott, Pfizer, and Eli Lilly. Ron is a visionary commercial expert and general manager who provides companies and boards with valuable understanding of how innovation, business models, corporate strategy, products, processes, and M&A will shape competition in a global market. He is a respected change leader adept at spearheading enterprise turnarounds, launching successful products to market, and asking the right questions to accelerate profitability, diversify the business and establish a culture of innovation.

Our Discovery

Diverse Biotech Innovation & Medical Discovery

Diverse Biotech, Inc., is not a “single-drug” or “single-disease” company.

Learn More